This study will determine the initial efficacy of phendimetrazine as a pharmacotherapy for cocaine dependence. A rigorous, inpatient human laboratory study will be conducted in which the subjective, physiological and reinforcing effects of cocaine are evaluated during maintenance on placebo and phendimetrazine.

Start Date01 Aug 2015

Sponsor / Collaborator

University of Kentucky

[+1]

100 Clinical Results associated with Phendimetrazine Tartrate

100 Translational Medicine associated with Phendimetrazine Tartrate

100 Patents (Medical) associated with Phendimetrazine Tartrate

591

Literatures (Medical) associated with Phendimetrazine Tartrate

01 Aug 2025·Journal of Infection and Public Health

Gender-specific weight-control behaviors : Utilizing the Narcotics Information Management System and Community Health Survey in 2020

Article

Author: Han, Euna ; Oh, Kyung Sun

BACKGROUND:

The prevalence of obesity and weight management differ by gender in Korea. This study aims to examine these differences by analyzing the patterns of pharmacological prescriptions of narcotic appetite suppressants and non-pharmacological weight control methods across genders.

METHODS:

This study utilized two datasets: the Community Health Survey (CHS), representing non-pharmacological interventions on a national scale, and the Narcotics Information Management System (NIMS), detailing pharmacological practices for weight control. The CHS provided data on obesity, physical activity, nutrition information, and lifestyle behaviors (smoking, drinking, walking), while NIMS data encompassed the use of narcotic appetite suppressants for weight management. A comparative analysis of the two data sources was conducted.

RESULTS:

Obesity rates were higher among men in their 30 s (51.3 %) and 40 s (46.5 %), whereas women showed increased obesity in their 50 s (25.7 %) and 60 s (31.4 %). Weight control attempts were more prevalent among women, who were more likely to engage in nutritional interventions and pharmacological treatments, particularly opioid appetite suppressants. Over 60 % of these prescriptions were given to women in their 30 s and 40 s, with phendimetrazine and phentermine being the most commonly prescribed. In men, the use of narcotic appetite suppressants was positively associated with high levels of physical activity (β = 9.16, 95 % CI: 2.92-15.41), while in women, prescriptions were associated with favorable health behaviors (β = 11.63, 95 % CI: 3.54-19.73).

CONCLUSIONS:

It is vital to recommend gender- and age-specific weight control strategies, both non-pharmacological and pharmacological. To prevent misuse, societal consensus on the appropriate prescription of narcotic appetite suppressants is crucial.

01 Jul 2025·PHYTOPARASITICA

Insecticidal, antifeedant, growth inhibitory effects, and molecular docking of Ageratina adenophora extract against Spilosoma obliqua

Author: Singh, Nilay ; Pal, Manoj K. ; Kumar, Arvind ; Pal, Ashutosh ; Sharma, Promila

Spilosoma obliqua (Walker), a polyphagous pest of the Arctiidae family, significantly damages various crops in India.Conventional chem. pesticides have limited effectiveness due to resistance, necessitating eco-friendly alternatives.This study evaluated the insecticidal, antifeedant, and growth inhibitory potential of hydroethanolic extract from Ageratina adenophora against S. obliqua larvae.High-resolution liquid chromatog.-mass spectroscopy identified 15 bioactive compounds, including L-valine (20.28%), 2-amino-6-[[1-(1-carboxy-2-methylpropoxy)-1-oxo-3-sulfanylpropan-2-yl]amino]-6-oxohexanoic acid (20.41%), oxalic acid dihydrate (9.08%), and aurantio-obtusin beta-D-glucoside (8.46%) being the most abundant.Other detected compounds include 1,1-Di(tetradecyl)benzimidazol-1-ium (5.56%), didrovaltratum (3.96%), di-Ph sulfoxide (3.52%), (E)-4-(Trimethylammonio)but-2-enoate (15.20%), adenosine (1.99%), 3,4-Methylenedioxymethamphetamine (0.84%), phendimetrazine (0.59%), coumarin (0.38%), 6-Amino-1-(3-carboxypropyl)-5-methyl-3-phenylpyridazin-1-ium (0.39%), and promegestone (0.38%).The insecticidal, antifeedant, and growth inhibitory activities of A. adenophora extract were evaluated using bioassays, and Lethal Concentration 50 (LC50) values were determined through probit anal.Statistical significance was assessed using ANOVA, followed by post-hoc tests to compare treatment effects.Bioassays demonstrated insecticidal activity, with LC50 values decreasing from 132.902 ppm at 24 h to 29.250 ppm at 72 h′ post-treatment.The extract exhibited a feeding deterrence index of 0.67 (67% deterrence) at 200 ppm and caused 24.56% growth inhibition at 72 h.Mol. docking and simulation studies against Ultraspiracle and Ecdysone Receptor proteins suggested potential interactions, with luteolin 7-O-glucuronide exhibiting the highest binding affinity.However, further biochem. validation is required to confirm these findings.These results suggest that A. adenophora extracts may serve as an eco-friendly alternative for sustainable pest management, which merits further field research.

01 Apr 2025·JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Simultaneous analysis of 203 drugs of abuse and metabolites in urine samples using liquid chromatography–tandem mass spectrometry

Article

Author: Choi, Seonmi ; Ryu, Eunbin ; Suh, Sungill ; Kwon, Chan Hyeok ; Kim, Jin Young ; Jang, Dain ; Jung, Kikyung ; Cho, Hee-Jung ; Lee, Sangeun ; Lee, Jihyun ; Song, Jaewoo ; Pyo, Jea-Sung ; Han, Eunyoung ; Koo, Wonhee ; Hong, Youngmin ; Lim, Na Young

The issue of drug abuse is increasingly becoming a significant concern worldwide. However, the simultaneous detection of a wide spectrum of drug of abuse (DOA), especially in biofluids, is challenging due to their diverse and varied physicochemical properties and matrix effects. Herein, we have developed a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous detection of 203 DOAs, including amphetamines, opiates, cathinones, phencyclidines, synthetic cannabinoids, cocaine, and metabolites, in 100 μL of urine. A mass analysis was performed using multiple reaction monitoring mode with an electrospray ionization source. The run time of the developed method was 16 min. Two sample preparation methods were compared for urine samples: enzymatic hydrolysis followed by either dilution or QuEChERS. Both methods demonstrated good linearity and low matrix effects; however, the dilution method showed superior accuracy and precision. Method validation was conducted to assess the efficacy of the developed method. The LC-MS/MS method with the dilution method demonstrated good linearity with the coefficients of determination (R²) above 0.99 for 200 compounds. The limit of quantification (LOQ) ranged from 0.1 to 20.0 ng/mL. The inter-day precision was below 20 % for all 203 compounds, with a bias of ±20 % for 198 compounds. This method was successfully applied to 40 real urine samples. The developed method allows the simultaneous separation and detection of a variety of DOAs with diverse physicochemical properties in a small amount of urine. Furthermore, the technique could be adapted to fit the practical requirements of forensic investigations, thereby enhancing its effectiveness and reliability.

News (Medical) associated with Phendimetrazine Tartrate

02 Oct 2024

·www.globenewswire.com

OrganOx metra® System Approved for Liver Transplantation in Canada

2025 commercial launch planned to expand access to this platform technologyOXFORD, England and MADISON, N.J., Oct. 02, 2024 (GLOBE NEWSWIRE) -- OrganOx Ltd, a world-leading organ medical technology company, today announced Health Canada has approved the OrganOx metra® System for use during liver transplantation. The OrganOx metra® System is currently commercially available for liver transplantation in the U.S., the U.K., and the European Union. The company plans to commercially launch the system in Canada in 2025. The OrganOx metra® System utilizes normothermic machine perfusion, or NMP, to circulate oxygenated blood, medications, and nutrients to donated organs at normal body temperature and near physiological conditions. This innovative technology extends organ preservation time, allows pre-transplant clinical assessment of organ viability and can dramatically improve operational logistics for both transplant teams and patients.1 “We are thrilled to receive this authorization in Canada, further advancing our vision to improve clinical outcomes for liver transplant patients around the globe,” said Craig Marshall, CEO of OrganOx. “In the coming months we look forward to introducing the metra® to transplant centers across Canada.” The performance of the metra® system has been evaluated across several clinical trials including the Consortium for Organ Preservation in Europe (COPE) European Trial, the first randomized trial to assess machine perfusion versus static cold storage in liver transplantation. Compared with static cold storage, the OrganOx metra® achieved a 50% lower level of graft injury despite a 54% longer mean preservation time.2 About OrganOxOrganOx is a commercial stage organ technology company with a focus on the preservation of isolated organs, spun out of the University of Oxford in 2008. The company’s first product, the OrganOx metra® normothermic machine perfusion (NMP) system for the liver, has been used to support more than 4,000 liver transplant operations globally, optimizing the use of donated organs by enabling assessment of the quality of livers as well as longer preservation durations. Other applications, including in kidney transplantation, are in development. Learn more at www.organox.com. About OrganOx metra®OrganOx metra® is a fully automated NMP device that enables continuous monitoring and evaluation of the liver, empowering surgeons to make evidence-based decisions on whether to transplant a donor organ and enabling viability testing.1 metra® is commercially available in UK (UKCA: 772261), European Union (CE Mark: MDR 772263 and MDR 772678) and the United States (FDA Approved: P200035). ContactsInvestor Relations:Steve DeitschChief Financial Officer, OrganOxinvestorrelations@organox.com Media:Emma YangHealth+Commerceemma@healthandcommerce.com References: Watson, C.J.E, Gaurav, R., Fear, C. et al. Predicting Early Allograft Function After Normothermic Machine Perfusion. Transplantation 106(12): 2391–2398 (2022) https://doi.org/10.1097/TP.0000000000004263Nasralla, D., Coussios, C.C., Mergental, H. et al. A randomized trial of normothermic preservation in liver transplantation. Nature 557, 50–56 (2018). https://doi.org/10.1038/s41586-018-0047-9

Clinical Study

100 Deals associated with Phendimetrazine Tartrate

External Link

KEGG	Wiki	ATC	Drug Bank
D02080	Phendimetrazine Tartrate	A08A	DB01579

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	United States	ACERTIS PHARMACEUTICALS, LLC	16 Apr 1979

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis